AddGraft Therapeutics
June 23, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Regenerative Medicine
AddGraft has reimagined autologous cell therapy by transforming engineered skin cells into living biofactories for durable protein production, enabling local or systemic activity across a variety of indications. Our non-viral transfection enables genomic insertion of up to 100kb of DNA with low COGS, and our topical “liquid graft” formulation lets us treat any wound site in an outpatient procedure. Our beachhead indication is the rare disease recessive dystrophic epidermolysis bullosa. Our engineered cells were used successfully to treat two human RDEB wounds in a Chinese IIT, and we can't wait to bring this platform to more patients in need.
Company HQ City:
Oakland
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2021
CEO
Nick Bayhi
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}